☆ 4.6 Article

Thiazolidinedione Use Is Associated with a Borderline Lower Risk of Multiple Myeloma and a Significantly Lower Risk of Death in Patients with Type 2 Diabetes Mellitus in Taiwan

CANCERS (2023)

Related references

Note: Only part of the references are listed.

Article Biochemistry & Molecular Biology

Prevalence of smoldering multiple myeloma based on nationwide screening

Sigrun Thorsteinsdottir et al.

Summary: This study investigated the epidemiological characteristics of smoldering multiple myeloma (SMM) in the general population of Iceland. The prevalence of SMM in individuals 40 years or older was found to be 0.53%, with higher rates in men (0.67%) than in women (0.39%). The high prevalence of SMM has important implications for future treatment policies in multiple myeloma.

NATURE MEDICINE (2023)

Add to Collection

Article Oncology

Pim-2 Kinase Regulates Energy Metabolism in Multiple Myeloma

Zhaoyun Liu et al.

Summary: This study investigates the role of Pim-2 kinase in regulating the metabolism and proliferation of multiple myeloma (MM) cells. The findings suggest that Pim-2 kinase directly regulates glycolysis, energy production, and survival in MM cells and may serve as a potential target for MM treatment.

CANCERS (2023)

Add to Collection

Article Andrology

Pioglitazone and Prostate Cancer Risk in Taiwanese Male Patients with Type 2 Diabetes: A Retrospective Cohort Study

Chin-Hsiao Tseng

Summary: This study found an association between the use of pioglitazone and a lower risk of prostate cancer. Among patients using pioglitazone, a cumulative duration of therapy greater than 20.23 months or a cumulative dose greater than 15,330 mg was associated with a significantly reduced risk of prostate cancer, primarily in patients aged less than 65 years.

WORLD JOURNAL OF MENS HEALTH (2023)

Add to Collection

Review Biochemistry & Molecular Biology

Effects of Peroxisome Proliferator-Activated Receptor-Gamma Agonists on Cognitive Function: A Systematic Review and Meta-Analysis

Hongfei Zhong et al.

Summary: Diabetes is a risk factor for dementia, and PPAR-gamma agonists not only have glucose-lowering effects but also can decrease cognitive impairment. Early intervention and high-dose therapy with PPAR-gamma agonists are beneficial for patients, with PIO showing better clinical effects and safety compared to RSG. Thus, PPAR-gamma agonists play an important role in the inflammatory response of AD or DM patients, and relevant metabolic indices should be considered in clinical therapeutics.

BIOMEDICINES (2023)

Add to Collection

Review Gastroenterology & Hepatology

Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials

Jihyun An et al.

Summary: Nonalcoholic fatty liver disease (NAFLD) is the leading cause of liver disease worldwide and its prevalence is on the rise. Nonalcoholic steatohepatitis (NASH), an advanced form of NAFLD, is characterized by liver cell injury, inflammation, and fibrosis. While there are currently no approved pharmaceutical treatments for NAFLD, medications such as Vitamin E and pioglitazone have shown effectiveness in resolving NASH. Additionally, new therapies targeting the underlying mechanisms of NASH, including bile acid signaling, insulin resistance, and lipid metabolism, are in development.

CLINICAL AND MOLECULAR HEPATOLOGY (2023)

Add to Collection

Article Oncology

Sodium-glucose cotransporter 2 (SGLT2) inhibitors and non-small cell lung cancer survival

Juhua Luo et al.

Summary: A study shows that the use of SGLT2 inhibitors is associated with improved overall survival in non-small cell lung cancer patients with pre-existing diabetes, even after considering potential confounders. This study provides evidence for the potential role of SGLT2 inhibitors in the treatment of non-small cell lung cancer.

BRITISH JOURNAL OF CANCER (2023)

Add to Collection

Review Oncology

An overview of pim kinase as a target in multiple myeloma

Zhaoyun Liu et al.

Summary: Multiple myeloma (MM) is a common hematologic malignancy characterized by clonal proliferation of plasma cells in the bone marrow. High expression and activity of pim kinase have been associated with the progression and prognosis of malignant diseases, making it a potential therapeutic target in the treatment of MM. Pim kinase inhibitors have shown good efficacy in clinical trials. This study reviews the role of pim kinase in the proliferation of myeloma cells, progression of bone disease infiltration, and regulation of the immune microenvironment in MM, as well as summarizes the effectiveness of pim kinase inhibitors as single agents or in combination therapy.

CANCER MEDICINE (2023)

Add to Collection

Review Oncology

Vitamin D and Multiple Myeloma: A Scoping Review

Naghmeh Mirhosseini et al.

Summary: As the global incidence of multiple myeloma (MM) increases, maintaining optimal vitamin D status is important for disease prevention. A review of human-level research found that vitamin D deficiency is common among MM patients, but there is limited evidence on the association between vitamin D status and the risk of developing MM. Future studies should explore the possible associations of vitamin D with disease staging, peripheral neuropathy, and survival/prognosis in MM patients, as well as investigate the role of vitamin D receptor (VDR) polymorphisms in MM.

CURRENT ONCOLOGY (2023)

Add to Collection

Review Medicine, General & Internal

Diagnosis and Management of Multiple Myeloma A Review

Andrew J. Cowan et al.

Summary: Multiple myeloma is a hematologic malignancy characterized by abnormal plasma cells in the bone marrow, often leading to anemia, bone disease, and kidney injury. Diagnosis involves measuring various biomarkers, while treatment options include chemotherapy, autologous hematopoietic stem cell transplantation, and maintenance therapy.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)

Add to Collection

Article Hematology

Multiple myeloma: 2022 update on diagnosis, risk stratification, and management

S. Vincent Rajkumar

Summary: Multiple myeloma is a hematologic malignancy that accounts for approximately 10% of cases. The diagnosis is based on the presence of clonal bone marrow plasma cells and associated symptoms. High-risk patients require stem cell transplantation and may benefit from different treatment regimens.

AMERICAN JOURNAL OF HEMATOLOGY (2022)

Add to Collection

Review Endocrinology & Metabolism

Diabetes mellitus and multiple myeloma; common features of two distinct entities

Anastasios Tentolouris et al.

Summary: Diabetes mellitus (DM) and multiple myeloma (MM) have a correlation, with diabetes potentially increasing the risk of developing MM and MM potentially affecting the course of diabetes. Metformin and pioglitazone may have positive effects on MM, and no clinically significant interactions have been observed between antidiabetic agents and antimyeloma drugs. Assessment of glucose intolerance risk factors and close monitoring of glucose levels are recommended for MM patients.

DIABETES-METABOLISM RESEARCH AND REVIEWS (2022)

Add to Collection

Review Oncology

Does DPP-IV Inhibition Offer New Avenues for Therapeutic Intervention in Malignant Disease?

Petr Busek et al.

Summary: There is growing interest in the effects of antidiabetic agents on cancer risk, progression, and treatment. Dipeptidyl peptidase-IV (DPP-IV) inhibitors, currently used in patients with type 2 diabetes, have been shown to have potential applications in cancer prevention and treatment. However, there are potential risks associated with DPP-IV inhibition in cancer, and further research is needed to fully understand the impact of these medications on cancer.

CANCERS (2022)

Add to Collection

Review Chemistry, Medicinal

The medicinal perspective of 2,4-thiazolidinediones based ligands as antimicrobial, antitumor and antidiabetic agents: A review

Gurpreet Singh et al.

Summary: 2,4-Thiazolidinedione (2,4-TZD), also known as glitazone, is a versatile pharmacophore with a wide range of pharmacological activities. Its potential for structural modification has attracted the attention of medicinal chemists. This review covers the recent development of TZD derivatives as antimicrobial, anticancer, and antidiabetic agents, along with different synthetic methods and the importance of structural modifications.

ARCHIV DER PHARMAZIE (2022)

Add to Collection

Review Oncology

SGLT-2 Inhibitors in Cancer Treatment-Mechanisms of Action and Emerging New Perspectives

Mieczyslaw Dutka et al.

Summary: Cancer remains a major cause of death worldwide despite significant advances in its treatment. A new group of antidiabetic drugs, called sodium-glucose cotransporter 2 inhibitors, have recently been found to have beneficial effects in heart failure and renal failure patients, as well as exhibit anticancer effects. However, the mechanisms of their anticancer action are not yet fully understood.

CANCERS (2022)

Add to Collection

Article Chemistry, Medicinal

Pioglitazone Has a Null Association with Inflammatory Bowel Disease in Patients with Type 2 Diabetes Mellitus

Chin-Hsiao Tseng

Summary: This study investigated the potential effects of pioglitazone on inflammatory bowel disease (IBD). Using a nationwide database, the researchers found that pioglitazone did not have any significant impact on IBD risk in patients with type 2 diabetes mellitus.

PHARMACEUTICALS (2022)

Add to Collection

Review Endocrinology & Metabolism

Adipocyte-Cancer Cell Interactions in the Bone Microenvironment

Meredith O. C. Otley et al.

Summary: The interaction between bone marrow resident adipocytes and other cells in their microenvironment is not well understood. Bone marrow adipocytes can influence bone metastasis and cancer cell growth through secretion of lipids, cytokines, and adipokines. Recent studies have highlighted the impact of bone marrow adipose tissue volume expansion on bone metastasis from solid tumors and blood cancers. The complex cross-talk between adipocytes and metastatic cells of lung and prostate cancer is also examined.

FRONTIERS IN ENDOCRINOLOGY (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Thiazolidin-2,4-Dione Scaffold: An Insight into Recent Advances as Antimicrobial, Antioxidant, and Hypoglycemic Agents

Harsh Kumar et al.

Summary: Heterocyclic compounds containing nitrogen and sulfur, especially thiazole derivatives, have attracted special interest due to their wide range of biological activities and applications in pharmaceuticals and agrochemicals. In this review, the research on thiazolidin-2,4-dione (TZD) derivatives as antimicrobial, antioxidant, and antihyperglycemic agents from 2010 to the present date is summarized, including their molecular mechanisms and information on patents granted to TZD analogues.

MOLECULES (2022)

Add to Collection

Article Multidisciplinary Sciences

Sodium-glucose cotransporter 2 (SGLT2) inhibitor initiation and hepatocellular carcinoma prognosis

Michael Hendryx et al.

Summary: This study found that the initiation of SGLT2 inhibitors is associated with improved overall survival and reduced mortality risk for HCC patients with pre-existing type 2 diabetes.

PLOS ONE (2022)

Add to Collection

Review Immunology

Multiple myeloma metabolism - a treasure trove of therapeutic targets?

Monica Roman-Trufero et al.

Summary: Multiple myeloma is an incurable cancer of plasma cells that primarily affects the bone marrow. This article discusses the major metabolic characteristics of plasma cells and myeloma cells, their roles in disease progression, and potential therapeutic applications. It also explores the complex relationship between myeloma cells and the bone marrow microenvironment.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Endocrinology & Metabolism

Novel thiazolidinedione analog reduces a negative impact on bone and mesenchymal stem cell properties in obese mice compared to classical thiazolidinediones

Andrea Benova et al.

Summary: The novel TZD analog MSDC-0602K showed improved bone parameters and reduced detrimental effects on bone marrow mesenchymal stem cell metabolism in obese mice compared to traditional TZDs, suggesting potential therapeutic use in both metabolic and bone diseases.

MOLECULAR METABOLISM (2022)

Add to Collection

Article Oncology

Second Primary Malignancy Risk in Multiple Myeloma from 1975 to 2018

Jing Wang et al.

Summary: As survival times for multiple myeloma (MM) patients continue to extend, the risk of developing a second primary malignancy (SPM) among MM survivors is a growing concern. This study evaluated the risk and survival of SPM among MM survivors from 1975 to 2018 using the Surveillance, Epidemiology, and End Results (SEER) 9 Registry Database. Factors such as age, sex, race, and time of MM diagnosis were found to be associated with SPM occurrence. The study suggests the need for site- and time-specific surveillance strategies to monitor SPM in high-risk MM patients.

CANCERS (2022)

Add to Collection

Review Oncology

How Far beyond Diabetes Can the Benefits of Glucagon-like Peptide-1 Receptor Agonists Go? A Review of the Evidence on Their Effects on Hepatocellular Carcinoma

Konstantinos Arvanitakis et al.

Summary: GLP-1 receptor agonists may play a significant role in the treatment of hepatocellular carcinoma by regulating molecular pathways involved in inflammation, tumor cell proliferation, and oxidative stress. However, further studies are needed to evaluate the risk-to-benefit ratio of using GLP-1 receptor agonists in patients with HCC.

CANCERS (2022)

Add to Collection

Review Medicine, General & Internal

An Update on the Current and Emerging Use of Thiazolidinediones for Type 2 Diabetes

Rosaria Vincenza Giglio et al.

Summary: Adequate glycemic control is crucial in preventing or reducing complications of type 2 diabetes mellitus. PPAR-gamma agonists, such as glitazones, are no longer prioritized due to their impact on heart failure. However, combining these drugs with innovative therapies could help mitigate the risk factors associated with metabolic syndrome. Though controversial, glitazones have shown scientific evidence of their effects on cardiometabolic, hematological, and neurological conditions, highlighting their potential usefulness.

MEDICINA-LITHUANIA (2022)

Add to Collection

Review Hematology

The Association between Metabolic Syndrome and Multiple Myeloma

Sophie C. Ragbourne et al.

Summary: Multiple myeloma is a hematological malignancy involving monoclonal proliferation of plasma cells leading to the presence of paraproteins in serum. There is a connection between paraproteins, metabolic syndrome features, inflammatory cytokines, and the development of MM. Some drugs used in treating metabolic syndrome, such as statins and metformin, may improve outcomes in MM.

ACTA HAEMATOLOGICA (2021)

Add to Collection

Review Hematology

Second primary malignancies in multiple myeloma: A review

Christina Poh et al.

Summary: As survival times of multiple myeloma patients improve, the risk of second primary malignancies becomes more relevant among survivors. Long-term use of certain medications and treatments may increase the risk of SPM, but most studies suggest that the benefits of therapy outweigh the risks of SPM.

BLOOD REVIEWS (2021)

Add to Collection

Review Cardiac & Cardiovascular Systems

Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug

Lorenzo Nesti et al.

Summary: Pioglitazone, a widely used insulin sensitizer drug for type 2 diabetes mellitus, has shown inconsistent effects on cardiac function with no direct harm proven. Despite an increased risk of heart failure hospitalization due to fluid retention, it is consistently associated with reduced risk of myocardial infarction and ischemic stroke. Additionally, it has beneficial effects on various cardiovascular parameters.

CARDIOVASCULAR DIABETOLOGY (2021)

Add to Collection

Review Oncology

PPAR-γ Modulators as Current and Potential Cancer Treatments

Tiange Chi et al.

Summary: PPARs are lipid sensors and metabolic regulators, with PPAR-γ showing potential in inhibiting cell proliferation, inducing apoptosis, and disrupting inflammation. However, safety concerns including drug interactions need to be addressed for clinical applications.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study

Stephen A. Harrison et al.

JOURNAL OF HEPATOLOGY (2020)

Add to Collection

Review Gastroenterology & Hepatology

Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease

Kyung-Soo Kim et al.

CLINICAL AND MOLECULAR HEPATOLOGY (2020)

Add to Collection

Review Environmental Sciences

Ionising radiation as a risk factor for lymphoma: a review

Richard W. Harbron et al.

JOURNAL OF RADIOLOGICAL PROTECTION (2020)

Add to Collection

Article Multidisciplinary Sciences

Is the risk of second primary malignancy increased in multiple myeloma in the novel therapy era? A population-based, retrospective cohort study in Taiwan

Yanfang Liu et al.

SCIENTIFIC REPORTS (2020)

Add to Collection

Article Oncology

Chinese Herbal Medicine Is Helpful for Survival Improvement in Patients With Multiple Myeloma in Taiwan: A Nationwide Retrospective Matched-Cohort Study

Chia-Yu Huang et al.

INTEGRATIVE CANCER THERAPIES (2020)

Add to Collection

Article Oncology

Association of BMI, Smoking, and Alcohol with Multiple Myeloma Mortality in Asians: A Pooled Analysis of More than 800,000 Participants in the Asia Cohort Consortium

Tomotaka Ugai et al.

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2019)

Add to Collection

Article Pharmacology & Pharmacy

Association Between Pioglitazone Use and Prostate Cancer: A Population-Based Case-Control Study in the Han Population

Li-Ting Kao et al.

JOURNAL OF CLINICAL PHARMACOLOGY (2019)

Add to Collection

Article Hematology

Unique anti-myeloma activity by thiazolidine-2,4-dione compounds with Pim inhibiting activity

Shiro Fujii et al.

BRITISH JOURNAL OF HAEMATOLOGY (2018)

Add to Collection

Article Oncology

Epidemiology of multiple myeloma in Taiwan, a population based study

Chao-Hsiun Tang et al.

CANCER EPIDEMIOLOGY (2018)

Add to Collection

Article Oncology

Multiple Myeloma and Its Precursor Disease Among Firefighters Exposed to the World Trade Center Disaster

Ole Landgren et al.

JAMA ONCOLOGY (2018)

Add to Collection

Article Endocrinology & Metabolism

Association of Pioglitazone with Increased Risk of Prostate Cancer and Pancreatic Cancer: A Functional Network Study

Weiheng Wen et al.

DIABETES THERAPY (2018)

Add to Collection

Article Medicine, General & Internal

Pioglitazone Reduces Dementia Risk in Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Analysis

Chin-Hsiao Tseng

JOURNAL OF CLINICAL MEDICINE (2018)

Add to Collection

Review Oncology

Second primary malignancies in multiple myeloma: an overview and IMWG consensus

P. Musto et al.

ANNALS OF ONCOLOGY (2017)

Add to Collection

Article Oncology

PATHOBIOLOGY AND DIAGNOSIS OF MULTIPLE MYELOMA

Kevin Brigle et al.

SEMINARS IN ONCOLOGY NURSING (2017)

Add to Collection

Article Oncology

Use of metformin and risk of kidney cancer in patients with type 2 diabetes

Chin-Hsiao Tseng

EUROPEAN JOURNAL OF CANCER (2016)

Add to Collection

Article Medicine, General & Internal

Pioglitazone after Ischemic Stroke or Transient Ischemic Attack

W. N. Kernan et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Multidisciplinary Sciences

Prevalence and Mortality-Related Factors of Multiple Myeloma in Taiwan

Jia-Hong Chen et al.

PLOS ONE (2016)

Add to Collection

Review Oncology

Multiple myeloma epidemiology and survival: A unique malignancy

Dickran Kazandjian

SEMINARS IN ONCOLOGY (2016)

Add to Collection

Review Pharmacology & Pharmacy

2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) role in hematopoiesis and in hematologic diseases: A critical review

Nicola Stefano Fracchiolla et al.

TOXICOLOGY (2016)

Add to Collection

Review Oncology

Smoldering Multiple Myeloma: Emerging Concepts and Therapeutics

Srinath Sundararajan et al.

CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2016)

Add to Collection

Article Endocrinology & Metabolism

Evaluation of exposure to pioglitazone and risk of prostate cancer: a nested case-control study

Naomi Boxall et al.

BMJ OPEN DIABETES RESEARCH & CARE (2016)

Add to Collection

Review Oncology

An Updated Review on Cancer Risk Associated with Incretin Mimetics and Enhancers

Chin-Hsiao Tseng et al.

JOURNAL OF ENVIRONMENTAL SCIENCE AND HEALTH PART C-ENVIRONMENTAL CARCINOGENESIS & ECOTOXICOLOGY REVIEWS (2015)

Add to Collection

Article Medicine, General & Internal

Risk of Early Mortality in Patients With Newly Diagnosed Multiple Myeloma

Pei Hsu et al.

MEDICINE (2015)

Add to Collection

Article Mathematical & Computational Biology

Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies

Peter C. Austin et al.

STATISTICS IN MEDICINE (2015)

Add to Collection

Article Oncology

A Pooled Analysis of Cigarette Smoking and Risk of Multiple Myeloma from the International Multiple Myeloma Consortium

Gabriella Andreotti et al.

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2015)

Add to Collection

Review Oncology

A Review on Thiazolidinediones and Bladder Cancer in Human Studies

Chin-Hsiao Tseng

JOURNAL OF ENVIRONMENTAL SCIENCE AND HEALTH PART C-ENVIRONMENTAL CARCINOGENESIS & ECOTOXICOLOGY REVIEWS (2014)

Add to Collection

Article Oncology

Rosiglitazone suppresses angiogenesis in multiple myeloma via downregulation of hypoxia-inducible factor-1α and insulin-like growth factor-1 mRNA expression

Mingzhong Rui et al.

MOLECULAR MEDICINE REPORTS (2014)

Add to Collection

Article Oncology

Rosiglitazone is not associated with an increased risk of bladder cancer

Chin-Hsiao Tseng

CANCER EPIDEMIOLOGY (2013)

Add to Collection

Article Multidisciplinary Sciences

Time Trend of Multiple Myeloma and Associated Secondary Primary Malignancies in Asian Patients: A Taiwan Population-Based Study

Huey-En Tzeng et al.

PLOS ONE (2013)

Add to Collection

Article Gastroenterology & Hepatology

Diabetes, insulin use and Helicobacter pylori eradication: a retrospective cohort study

Chin-Hsiao Tseng

BMC GASTROENTEROLOGY (2012)

Add to Collection

Article Endocrinology & Metabolism

Pioglitazone and Bladder Cancer A population-based study of Taiwanese

Chin-Hsiao Tseng

DIABETES CARE (2012)

Add to Collection

Article Hematology

Pre-existing diabetes mellitus in patients with multiple myeloma

Yi-Sheng Chou et al.

EUROPEAN JOURNAL OF HAEMATOLOGY (2012)

Add to Collection

Review Oncology

Peroxisome Proliferator-Activated Receptor Agonists and Bladder Cancer: Lessons from Animal Studies

Chin-Hsiao Tseng et al.

JOURNAL OF ENVIRONMENTAL SCIENCE AND HEALTH PART C-ENVIRONMENTAL CARCINOGENESIS & ECOTOXICOLOGY REVIEWS (2012)

Add to Collection

Review Medicine, General & Internal

Pioglitazone and bladder cancer in human studies: Is it diabetes itself, diabetes drugs, flawed analyses or different ethnicities?

Chin-Hsiao Tseng

JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION (2012)

Add to Collection

Article Endocrinology & Metabolism

Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone Interim report of a longitudinal cohort study

James D. Lewis et al.

DIABETES CARE (2011)

Add to Collection

Review Oncology

Body mass index and risk of multiple myeloma: A meta-analysis of prospective studies

Alice Wallin et al.

EUROPEAN JOURNAL OF CANCER (2011)

Add to Collection

Article Endocrinology & Metabolism

Obesity related hyperinsulinaemia and hyperglycaemia and cancer development

Susen Becker et al.

ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY (2011)

Add to Collection

Article Cardiac & Cardiovascular Systems

Optimal anthropometric factor cutoffs for hyperglycemia, hypertension and dyslipidemia for the Taiwanese population

Chin-Hsiao Tseng et al.

ATHEROSCLEROSIS (2010)

Add to Collection

Article Oncology

High endoplasmic reticulum activity renders multiple myeloma cells hypersensitive to mitochondrial inhibitors

Metin Kurtoglu et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)

Add to Collection

Article Hematology

Peroxisome proliferator-activated receptor γ agonists potentiate the cytotoxic effect of valproic acid in multiple myeloma cells

Nassera Aouali et al.

BRITISH JOURNAL OF HAEMATOLOGY (2009)

Add to Collection

Article Hematology

All-trans retinoic acid can intensify the growth inhibition and differentiation induction effect of rosiglitazone on multiple myeloma cells

Haiwen Huang et al.

EUROPEAN JOURNAL OF HAEMATOLOGY (2009)

Add to Collection

Article Oncology

Peroxisome Proliferator-Activated Receptor γ Overexpression Suppresses Growth and Induces Apoptosis in Human Multiple Myeloma Cells

Tatiana M. Garcia-Bates et al.

CLINICAL CANCER RESEARCH (2008)

Add to Collection

Article Oncology

Activation of adenosine monophosphate activated protein kinase inhibits growth of multiple myeloma cells

Philipp Baumann et al.

EXPERIMENTAL CELL RESEARCH (2007)

Add to Collection

Article Endocrinology & Metabolism

Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia

Mark A. Deeg et al.

DIABETES CARE (2007)

Add to Collection

Article Oncology

Epidemiology of multiple myeloma in Taiwan - Increasing incidence for the past 25 years and higher prevalence of extramedullary myeloma in patients younger than 55 years

Shang-Yi Huang et al.

CANCER (2007)

Add to Collection

Article Public, Environmental & Occupational Health

Bias in occupational epidemiology studies

Neil Pearce et al.

OCCUPATIONAL AND ENVIRONMENTAL MEDICINE (2007)

Add to Collection

Article Medicine, General & Internal

Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes

Steven E. Nissen et al.

NEW ENGLAND JOURNAL OF MEDICINE (2007)

Add to Collection

Article Oncology

Peroxisome proliferator-activated receptor-γ antagonists exhibit potent antiproliferative effects versus many hematopoietic and epithelial cancer cell lines

Jack D. Burton et al.

ANTI-CANCER DRUGS (2007)

Add to Collection

Article Endocrinology & Metabolism

Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues

Nathan K. LeBrasseur et al.

AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2006)

Add to Collection

Article Endocrinology & Metabolism

Chronic rosiglitazone treatment restores AMPKα2 activity in insulin-resistant rat skeletal muscle

SJ Lessard et al.

AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2006)

Add to Collection

Article Endocrinology & Metabolism

Pioglitazone with sulfonylurea: glycemic and lipid effects in Taiwanese type 2 diabetic patients

CH Tseng et al.

DIABETES RESEARCH AND CLINICAL PRACTICE (2005)

Add to Collection

Article Endocrinology & Metabolism

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

RB Goldberg et al.

DIABETES CARE (2005)

Add to Collection

Article Oncology

RWJ-241947 (MCC-555), a unique peroxisome proliferator-activated receptor-γ ligand with antitumor activity against human prostate cancer in vitro and in beige/nude/x-linked immunodeficient mice and enhancement of apoptosis in myeloma cells induced by arsenic trioxide

T Kumagai et al.

CLINICAL CANCER RESEARCH (2004)

Add to Collection

Article Immunology

Transcriptional inactivation of STAT3 by PPARγ suppresses IL-6-responsive multiple myeloma cells

LH Wang et al.

IMMUNITY (2004)

Add to Collection

Article Immunology

Human multiple myeloma cells express peroxisome proliferator-activated receptor γ and undergo apoptosis upon exposure to PPARγ ligands

DM Ray et al.

CLINICAL IMMUNOLOGY (2004)

Add to Collection

Article Oncology

Ligands of peroxisome proliferator-activated receptor γ induce apoptosis in multiple myeloma

J Eucker et al.

ANTI-CANCER DRUGS (2004)

Add to Collection

© Peeref 2019-2024. All rights reserved.